IQBAL JANGDA: Open Payments
NPI 1467537175 · LONG BEACH, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,322 in 15 payments from 10 companies in 2025. Trend: 2023 $1,131 · 2024 $1,863 · 2025 $1,322
Food & beverage: $1,322
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 5 | $227 |
| AstraZeneca Pharmaceuticals LP | 2 | $182 |
| Phathom Pharmaceuticals, Inc. | 1 | $149 |
| GlaxoSmithKline, LLC. | 1 | $125 |
| ABBVIE INC. | 1 | $124 |
| Lilly USA, LLC | 1 | $124 |
| Actelion Pharmaceuticals US, Inc. | 1 | $122 |
| Novo Nordisk Inc | 1 | $122 |
| Neurocrine BioSciences, Inc. | 1 | $119 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $29 |
Products named: COBENFY, VOQUEZNA, NUCALA, BREZTRI, QULIPTA, ZEPBOUND, UPTRAVI, Ozempic.
Industry payments across NY — which companies pay providers there.
